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Abstract
Background: Blood stream infections (BSIs) are a major cause of morbidity and mortality. The time from taking
blood cultures to obtain results of antibiotic sensitivity can be up to five days which impacts patient care. The
Alfred 60 AST™ can reduce laboratory time from positive culture bottle to susceptibility results from 16 to 25 h to
5–6 h, transforming patient care. To evaluate the diagnostic accuracy of a rapid antimicrobial susceptibility system,
the Alfred 60 AST™, in clinical isolates from patients with BSIs and confirm time to results. 301 Gram-negative and
86 Gram-positive isolates were analysed directly from positive blood culture bottles following Gram staining.
Antimicrobial susceptibility results and time-to-results obtained by rapid Alfred 60 AST system and BD Phoenix were
compared .
Results: A total of 2196 antimicrobial susceptibility test results (AST) were performed: 1863 Gram-negative and 333
Gram-positive. AST categorical agreement (CA) for Alfred 60 AST™ was 95% (1772/1863) for Gram-negative and 89%
(295/333) for Gram-positive isolates. Gram-negative CA: ampicillin 96% (290/301); ciprofloxacin 95% (283/297);
ceftriaxone 96% (75/78); meropenem 97% (288/297); piperacillin-tazobactam 95% (280/295); gentamicin 94% (279/
297) and amikacin 93% (277/298). The median time to susceptibility results from blood culture flagging positive was
6.3 h vs 20 h (p < 0.01) for Alfred system vs BD Phoenix™.
Conclusion: Alfred 60 AST system greatly reduced time to antimicrobial susceptibility results in Gram-negative and
Gram-positive BSIs with good performance and cost, particularly for Gram-negative bacteraemia.
Keywords: Rapid diagnostics. Bloodstream infection. Bacteraemia. Antimicrobial susceptibility testing. Gram-
negative bacteria. Gram-positive bacteria
Background
Blood stream infections (BSIs) are worldwide, a major
cause of morbidity and mortality [1]. The clinical labora-
tory plays a key role in the diagnosis of BSIs and pro-
vides antimicrobial susceptibility results which are
crucial in clinical decision-making. Blood cultures re-
main the main way to identify blood stream infection.
Despite optimisation in laboratory workflows that have
decreased time-to-result (Anderson, [2]), the time from
taking a blood culture to obtaining a result of antimicro-
bial susceptibilities can be up to 5 days [3]. The time to
positivity, time from blood culture collection to bottle
flagging positive, is typically 12 to 24 h [1]. The subse-
quent mean time to identify bacterial species and obtain
antimicrobial susceptibilities, using standard methods, is
a further 36 h [4] .
Phenotypic antimicrobial susceptibility tests (AST)
generally relies on detecting bacterial growth in the pres-
ence of antibiotic. Standard methods of testing used in
routine diagnostic laboratories for patient care include
broth or agar micro-dilution, disc diffusion or antibiotic
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gradient strips, which require around 24–72 h to
complete [5]. A number of automated systems for test-
ing antimicrobial susceptibility are increasingly used
such as BD Phoenix™ (Becton Dickinson, USA), VITEK-
2™ (BioMerieux, France) and MicroScan™ (Beckman,
USA) which have a time to results ranging between 12
and 24 h after positive culture [6].
The time to clinically useful antimicrobial susceptibil-
ity data has an impact on patient care either to change
to an effective antibiotic in the case of a resistant isolates
or to focus to a narrower spectrum antibiotic for suscep-
tible isolate. The development of rapid diagnostics is a
key aim in the control of the rise in antibiotic resistance
[7]. The use of genotypic methods such as nucleic acid
amplification tests to detect antibiotic resistance in rou-
tine blood cultures has not been widely adopted due to
high cost [8], lack of sensitivity when using blood direct
from the patient [9] and inability to detect many resist-
ance mechanisms and hence “rule-in” the use of antibi-
otics when no resistance marker is detected [10]. This
highlights the need to increase the speed of phenotypic
methods to shorten the time to obtain antimicrobial sus-
ceptibility results [11].
The Alfed 60 AST™ (Alifax, Italy) is a CE marked auto-
mated commercial laser-scattering based in-vitro diag-
nostic (IVD) providing antimicrobial susceptibility
results directly from positive blood culture bottles within
4–6 h. The Alfred 60 AST™ uses light scatter to detect
bacterial growth in a liquid culture broth. In brief, 30 μL
of blood from a positive blood culture is inoculated into
a broth that is incubated, then light scatter is measured
until it reaches a turbidity of 0.4–0.6 McFarland. A
series of tubes containing antibiotics are then robotically
inoculated and bacterial growth measured by light scat-
ter providing real time bacterial growth curves. Growth
curves of bacteria over 3–5 h in the tested antibiotics are
compared to growth a positive control (no antibiotic)
and percentage of inhibition of growth (%PIC) is calcu-
lated. The %PIC is compared between control and anti-
biotic tubes and reported as resistant, intermediate and
sensitive categories, according to the range of inhibition
(Sensitive result: Inhibition of growth > 65%; Intermedi-
ate: Inhibition of growth between 65 and 50%; Resistant:
Inhibition of growth < 50%). To grant a reliable detec-
tion of the growth inhibition (keeping as reference the
“Reference Vial”) a proper growth must be detected (≥
700.00 CFU/ml), if not the test is not considered valid.
The system is based on a light scattering technique, A
light laser beam which is oriented trough a sample and
two photo detectors placed at 30° and 90° receive signals
generated by the light scattered by the bacteria present
in the vial. Growth kinetic curves are obtained for each
detector and displayed in two curves. Double reading
channel (2 detectors) is important for samples with high
initial turbidity level. If 1 detector (the 1st one) becomes
saturated due to the high sample’s turbidity then the
2nd detector is able to detect signals. Finally, a mathem-
atical algorithm selects the best reading detector channel
for the calculation of the inhibition of growth. (Fig. 1).
The panel of antibiotics tested can be predefined by
users. Hands on time for each run is about 15 min. In
addition, the system requires a daily set up of approxi-
mately 10 min and a weekly maintenance wash out of
30 min. Up to 60 individual tests can be performed in a
run, the number of isolates tested depends on the num-
ber of antibiotics tested (for example 10 isolates may be
tested for 6 antibiotics each).
The time to result is unaffected by the number of anti-
biotics or samples tested. Alfred 60 AST recognizes each
reference vial followed by its respective antibiotic vials as
a single assay and has the capacity to initiate multiple
single susceptibility assays at the same time for different
isolates.
The purpose of this study was to compare the accur-
acy and speed of results of the Alfred 60 AST™ with the
BD Phoenix™ (Becton Dickinson, USA) automated sus-
ceptibility testing system, a broth-based microdilution
test that utilizes a redox indicator to enhance the detec-
tion of organism growth, which is the standard of care
in our routine diagnostic laboratory.
Results
Antimicrobial susceptibility results of Alfred 60 system
Antimicrobial susceptibility results were performed for
387 clinical positive blood culture bottles that were
monomicrobial on Gram stain (301 Gram-negative and
86 Gram-positive) with a total of 2196 individual anti-
microbial test results (1863 Gram-negative and 333
Gram-positive). Eighteen samples (5%) were excluded
from the analysis. Excluded samples comprised 3 poly-
microbial samples that were not detected during Gram
stain and 15 non valid results included 10 system tech-
nical failure before AST performance and 5 failures of
no bacterial growth in the reference vial on Alfred 60
AST system, including: 1 Acinetobacter baumanni; 1
Achromobacter spp; 1 Bacteroides fragilis; 1 Pseudo-
monas aeruginosa; 1 Klebsiella oxytoca.
71% (213/301) of the Gram-negative and 43% (37/86)
of the Gram-positive isolates were resistant to at least
one antibiotic. 9% (28/301) of the Gram-negative organ-
isms were identified as Extended-spectrum beta-
lactamases (ESBLs) as defined by BD Phoenix™ expert
rules for resistance. Fig. 3.
There were a total of 301 valid Alfred 60 AST results
for Gram-negative monomicrobial isolates. Data were
available on the following organisms: 209 E.coli; 57 Kleb-
siella spp; 10 P. aeruginosa; 12 Proteus spp; 7
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Enterobacter spp; 6 Morganella morgani. A total of 1863
AST results were produced and compared with BD
Phoenix™.
Alfred 60 AST agreement for gram-negative bacteria
Overall categorical agreement for Alfred 60 AST was
95% (1772/1863) for Gram-negative isolates (55 major
errors, 31 very major errors and 5 minor errors). The
highest agreement was observed with meropenem 97%
(288/297); ampicillin 96% (290/301); ciprofloxacin 95%
(283/297); ceftriaxone 96% (75/78) and piperacillin-
tazobactam 95% (280/295) Lower agreement was seen
for amikacin 93% (277/298) and gentamicin 94% (279/
297). Out of a total of 55 major errors, 65% (36/55) in-
volved E.coli against amikacin 13; gentamicin 8;
piperacillin-tazobactam 6; meropenem 3; ampicillin 4;
ciprofloxacin 2 and 20% (11/55) involved Klebsiella spp.
against ciprofloxacin 3; meropenem 3; amikacin 2; piper-
acillin/tazobactam 2. Very major errors were seen with
ciprofloxacin 6; ampicillin 7; gentamicin 7; piperacillin/
tazobactam 5; meropenem 3; ceftriaxone 2 and amikacin
1. Tables 1 and 2.
Fig. 1 A) represents the standard growth curve without presence of antibiotic (curves are displayed representing the light scattered signals
received by photodetectors placed at 30° and 90° from the laser beam). B) represents a sensitive or susceptible antimicrobial results. C)
Represents a resistant result, in the presence of antibiotic the growth curve is positive, comparable to the reference vial
Table 1 AST results of the Alfred 60AST™ system compared to BD Phoenix™ system for each antibiotic. Column 2 shows the total
number of susceptibility tests done with both methods; columns 3 to 6 the total number of tests for which there was agreement
within each category and in total; columns 8 to 10 the number of discrepancies; S = susceptible = intermediate, R = resistant, CA =
Categorical agreement, 95% CI = 95% confidence interval
No. of category agreements No. of discrepancies
Antimicrobial agent No. of AST results S R I CA Total CA % (95% CI) Minor Major Very major
Gram-negative antimicrobials
Ampicillin 301 88 202 0 290 96 (94–98) 0 4 7
Amikacin 298 273 2 2 277 93 (89–96) 3 17 1
Ciprofloxacin 297 222 61 0 283 95 (92–97) 1 7 6
Ceftriaxone 78 64 11 0 75 96 (89–99) 0 1 2
Gentamicin 297 240 38 1 279 94 (91–96) 1 10 7
Piperacillin/Tazobactam 295 263 16 1 280 95 (92–97) 0 10 5
Meropenem 297 284 4 0 288 97 (94–99) 0 6 3
Overall agreement 1863 1434 334 4 1772 95 (94–96) 5 (0.3%) 55 (3%) 31 (2%)
Gram-positive antimicrobials
Cefoxitin 75 34 35 0 69 92 (83–97) 0 4 2
Cindamycin 75 41 17 2 60 80 (69–88) 1 9 5
Teicoplanin 86 79 0 1 79 92 (84–97) 1 6 0
Vancomycin 86 76 1 0 77 90 (81–95) 0 9 0
Ampicillin 11 9 1 0 10 90 (59–100) 0 1 0
Overall agreement 333 239 54 3 295 89 (85–92) 2 (0.6%) 29 (9%) 7 (2%)
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Alfred 60 AST agreement for gram-positive bacteria
A total of 86 valid Gram-positive organisms were ana-
lysed giving a total of 333 Alfred 60 AST results. The
overall categorical agreement for Alfred 60 AST was
89% (295/333) for Gram-positive samples. The highest
agreement was observed with cefoxitin 92% (69/75) and
teicoplanin 92% (79/86) whilst clindamycin and vanco-
mycin showed the lowest one 80% (60/75) and 90% (77/
86) respectively. There were 29 major errors, 7 very
major errors and 2 minor errors. Seventeen of the major
errors (68%) involved S. aureus tested clindamycin 6, tei-
coplanin 6 and vancomycin 5. The remaining 12 major
errors involved CoNS and Enterococci Spp against vanco-
mycin and cefoxitin. Five of the very major errors in-
volved CoNS tested against clindamycin and two
involved S. aureus and Staphylococcus epidermidis tested
against cefoxitin. Tables 1 and 2.
Time to results
The median time to susceptibility results from flagging
positive blood cultures was 6.3 h (IQR = 5.25–8.4) for Al-
fred 60 AST system compared to the 20 h (IQR = 16–24)
for BD Phoenix™. As a result, a reduction in the turn-
around time by 13 h when compared to BD Phoenix™
was observed.
In terms of “hands-on-time”, in our experience, an
average time of 20 min were required to load the
samples on the Alfred rapid system, comparable to 15
min for BD Phoenix™ system. Table 3.
Discussion
This study shows the performance of Alfred 60 AST™
system, which significantly reduced the time to anti-
microbial susceptibility results. The overall categorical
agreement for Alfred 60 AST system was 96% for Gram-
negative and 90% for Gram-positive organisms. These
results are broadly comparable to an earlier smaller
study reported by Barnini et al [12], which compared the
Alfred 60 AST™ with VITEK-2™, and reported a categor-
ical agreement of 91% for enterobacteraciae and 94% for
staphylococci. Although similar, differences in the per-
formances may be due to the choice of antibiotics tested,
Barnini et al tested ceftazidime and gentamicin, but did
not test amoxicillin and ciprofloxacin.
Compared to the BD Phoenix, the overall categorical
agreement for Alfred 60 AST system was 96% for Gram-
negative and 90% for Gram-positive organisms. Previous
studies report the accuracy of the BD Phoenix™ system
for susceptibility results compared against agar dilution
and manual disc diffusion, showing categorical agree-
ment of 97.5% [13] and 95% (Donay, 2004) respectively.
Alfred 60AST™ system achieved a performance of over
95% CA compared to the BD Phoenix™ for all antibiotics
except amikacin and gentamicin. However, this new
Table 2 AST results of the Alfred 60 AST™ system compared to BD Phoenix™ system for 301 Gram-negative and 86 Gram-positive
organisms included in the study. Column 2 refers to the total number of susceptibility tests done with both methods; colum 3 refers
to the number of tests for which there was agreement between both tests. S = sensitivie, I = intermediate, R = resistant, CA =
Categorical agreement, 95% CI = 95% confidence interval. CoNS – Coagulase negative staphylococcus, 95%CI- 95% confidence
interval
No. of discrepancies
No. of Isolates No. of AST results No. of CA CA % (95% CI) Very major Major Minor
Gram-negative organisms
E.coli 209 1291 1242 96 (95–97) 9 36 4
Klebsiella spp 57 351 330 94 (91–96) 10 11 1
P.mirabillis 12 79 69 87 (78–84) 6 3 0
P.aeruginosa 10 61 58 95 (86–91) 0 3 0
E.cloacae 7 43 37 86 (72–95) 0 6 0
M.morgani 6 38 36 95 (82–99) 0 2 0
Overall Gram-negative 301 1863 1772 95 (94–96) 31 55 5
Gram-positive organisms
S.epidermidis 26 104 98 94 (88–98) 3 2 1
S.aureus 21 84 66 79 (68–87) 1 17 0
S.hominis 15 60 54 90 (79–96) 2 4 0
CoNS other 13 52 48 92 (81–97) 1 3 0
E.faecalis 10 30 27 93 (73–98) 0 3 0
E.faecium 1 3 2 67 (10–100) 0 0 1
Overall Gram-positive 86 333 295 89 (85–92) 7 29 2
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system showed slightly lower performance for Gram-
positive isolates and for glycopeptides and clindamycin.
In our study, the average hands-on time per specimen
was not different from routine testing, however the time
to deliver susceptibility results has been significantly re-
duced compared to routine standard automated system
(BD Phoenix™). The times to AST results were similar to
the times noted in a previous study using the Alfred 60
AST™ system and other the Accelerate Pheno™ system
(Accelerate Diagnostics, USA) [12] [15] [16] [17]. Given
high categorical agreement between the BD Phoenix™
and Alfred 60 AST™ and the 16 h reduction in time to
results there are compelling clinical benefits of the Al-
fred AST 60™.
The Accelerate Pheno™ system is an alternative rapid
phenotypic testing system. In studies using similar AST
comparator techniques, an agreement of 93.3% [18],
94.9% [19] and 96.4% respectively [15] has been re-
ported. Showing very similar diagnostic performance to
the Alfred AST 60™. The median time to AST results
from positive culture bottle to AST result for the Accel-
erate Pheno™ system is reported as 10.7 [8.6–12.8] hours
[15]. It should be noted that an advantage of the Accel-
erate Pheno™ system is that it identifies the species of
the isolate in addition to the sensitivity pattern. For this
reason, we needed to perform a rapid identification with
a MALDI-TOF MS at the same time as the Alfred 60
AST™.
A specific advantage of the Alfred 60 AST™ system
versus other rapid phenotypic susceptibility methods is
the capacity to accommodate between 7 and 9 isolates
per run, the number of samples may be varied according
to the customized antibiotic panel chosen by the user
and a satellite module provides extra capacity to handle
up to a total of 20 isolates per day. Furthermore, new
samples can be loaded during an ongoing run without
interfering previous loaded isolates.
The cost of performing rapid phenotypic sensitivity
testing for some systems has been regarded as high and
seen as a barrier to introducing these tests. We estimate
the additional reagent costs for the Alfred 60 AST™ of
€2–4 per antibiotic tested [20] or €30–40 per isolate,
with relatively minimal laboratory hands on time. This
cost is considerably lower than other rapid testing sys-
tems and we believe could be justified by the clinical
benefits.
One of the limitations of the system is it will not per-
form antimicrobial susceptibility testing on polymicro-
bial samples, although Gram-staining before using the
Alfred 60 AST™ meant polymicrobial samples were rela-
tively uncommon in these samples. Another possible
drawback is the absence of MIC values, which are not
provided on the susceptibility report, that may occasion-
ally be relevant for specific therapeutic decisions [21],
however most clinical decisions can be made simply with
an S/I/R result. Another limitation lies on the inability
of performing susceptibility testing of Acinetobacter bau-
mannii or Stenotrophomona maltophila which are emer-
ging as a challenging to treat nosocomial pathogens [22].
Furthermore, there are inconsistencies with the concen-
tration of cefoxitin in the Alfred 60 AST™ panel. The
EUCAST breakpoint for cefoxitin is 4 mg/L for S. aureus
and S. lugdunensis and 8 μg/L for Staphylococcus sapro-
phyticus, whilst Alfred 60AST™ breakpoint for all coagu-
lase negative Staphylococci is 8 μg/L.
Limitations of the study were that although broth
microdilution is considered the “gold standard” tech-
nique for antimicrobial susceptibility evaluation, this is
rarely routinely available in practice in clinical laborator-
ies. The BD Phoenix™ system is a well validated auto-
mated AST system [13]. Similar methodologies of
comparing rapid diagnostic tests with automated AST
systems in place of broth or agar dilution has been used
in majority of published studies [19] [16] [15] [17] [18]
[13].
We note the relatively small proportion of multi-
resistant microorganisms in our particular setting and
the fact that more than half of the susceptibility testing
for Gram-negative isolates were performed for E.coli
blood stream infections. Furthermore, a smaller number
of Gram-positive organisms were tested compared to the
Gram-negative organisms.
Even though there is clinical utility in rapid antimicro-
bial sensitivity results we would still recommend isolates
have further extensive testing with another system, such
as the BD Phoenix™ or a VITEK™ 2, to give a complete
sensitivity pattern to a wider range of antibiotics and
give results for minimum inhibitory concentrations.
Since, BD phoenix shows more accuracy specially for
gram positive bacteria.
The implementation of the Alfred 60 AST™ system in
the laboratory routine workflow, will provide rapid
Table 3 Turnaround time for results from blood culture positivity: Median Time (in hours) and Interquartile range from positive
blood culture to results of Alfred vs BD Phoenix™. Time in hours from positive blood culture to susceptibility results
Alfred 60 AST BD Phoenix™ system Alfred™ vs BD Phoenix™
Time to results from positive blood culture (h) 6.3 h (IQR, 5.25–8.25) 20 h (IQR, 16–24) p < 0.01
Technician “hands-on” time (min) 20 min (IQR, 10–30) 15 min (IQR, 10–20)
Technique Characteristics Direct culture bottle Agar plate subculture (4 h)
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susceptibility results, that effectively communicated to
clinicians might result in a prompt change to appropri-
ate antimicrobial treatment, antimicrobial resistance re-
duction and improved infection control [23] [24] [25].
Conclusions
In conclusion, Alfred 60 AST™ system has demonstrated
an improvement in the turn-around time of antimicrobial
phenotypic susceptibility results in Gram-negative and
Gram-positive blood stream infections in comparison with
automated AST techniques and conventional AST testing.
Whilst the system provided a notably good perform-
ance and high accuracy for Gram-negative bacteria, it
still needs improvements in Gram-positive AST results
and is less dependable for yeast detection [20].
Prospective studies are needed to further analyse the
impact and effects of the rapid diagnostic techniques
among bacteraemia patients and consequences of the
introduction of new available rapid automated systems
on antibiotic prescription against BSI and on clinical pa-
tient pathways.
Methods
Study setting
A prospective evaluation was conducted directly from
blood cultures, between January and May 2018 in the
microbiology laboratory of South West London Path-
ology in London. The diagnostic laboratory processes
approximately 3500 positive blood cultures per year. All
blood culture samples were initially incubated on the BD
BacTec FX400 (Becton Dickinson, USA). Blood culture
bottles, including adult and paediatric samples, that
flagged positive were then tested in parallel for anti-
microbial susceptibility by Alfred 60 AST and by routine
testing on the BD Phoenix™, after Gram staining per-
formance to determine a Gram-positive or Gram-
negative antibiotic panel required and exclude the poly-
microbial samples.
Bacterial species were identified by Bruker Biotyper
matrix assisted laser desorption ionization-time of flight
mass spectrometry (MALDI-TOF MS, Germany), this
technique was performed, as per routine laboratory
practice, from isolated colonies obtained following 4 h
agar plate subculture, in order to fully interpret the re-
sults of the Alfred 60AST with species ID. This meant
the species of the samples were identified before the Al-
fred 60AST result was available. (Fig. 2).
Alfred 60 AST system
The Alfred 60 ST was performed according to the man-
ufacturer’s instructions on blood culture bottle that had
flagged positive on the BD BacTec FX system, this
Fig. 2 Flowchart showing laboratory workflow followed along the rapid susceptibility system (Alfred 60 AST) evaluation. Once a blood culture
bottle flagged positive following incubation, Gram-stain was performed in order to distinguish between Gram-positive and Gram-negative
microorganism and exclude the polymicrobial ones, which will allow to select the appropriate antibiotic panel and a direct blood sample from
the bottle was loaded onto the rapid system. In parallel, the identification results were obtained by MALDI-TOF, performed from isolated colonies
obtained by 4 h agar plate subculture. The mean total time from positive blood culture to identification and susceptibility results was 6 h (approx)
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including running weekly controls with Pseudomonas
aeruginosa 27,853; E.coli 25,922; E.coli 35,218; S.aureus
29,213; E.faecalis 29,212; E. faecalis 51,299. 30 μL of the
sample was inoculated into an enrichment broth and
loaded onto the instrument. Each vial of antibiotic con-
tains 45 mg of a preparation of lyophilized antibiotic that
required to be dissolved in 2 mL of regenerating solu-
tion, as per manufacturer’s specifications. Some antibi-
otics, including amikacin, piperacillin-tazobactam and
meropenem, required different specific antibiotic vials
for testing Enterobacteriaceae and Pseudomonas Spp. As
the identity of organism is unknown when the Alfred 60
AST system was set up, a combined panel of antibiotics
with both concentrations was used. When the identity of
the organism was known the appropriate antibiotic re-
sult was reported.
Antimicrobial agents
The following antibiotic panel was performed on Alfred
60AST™ for all Gram-negative organisms (Enterobacteri-
aceae and Pseudomonas spp).: ampicillin, amikacin, cip-
rofloxacin, gentamicin, meropenem, and piperacillin-
tazobactam. Ceftriaxone was included on the Enterobac-
teriaceae panel later in March 2018 and tested in 78 iso-
lates. For Gram-positive organisms the antibiotic panel
included: ampicillin, cefoxitin, clindamycin, teicoplanin
and vancomycin. Purity plates were set up both on
CLED agar and blood agar plates and examined the next
day to confirm that the inoculum was not mixed.
Comparator AST technique
The BD Phoenix™ automated susceptibility testing sys-
tem CE marked IVD (BD Diagnostics, Sparks, MD,
USA) (software version 5.02H/4.11B) was used as the
routine laboratory method according to the manufac-
turer instructions, including running weekly controls
with Pseudomonas aeruginosa 27,853; E.coli 25,922;
E.coli 35,218; S.aureus 29,213; E.faecalis 29,212; E. faeca-
lis 51,299 using cartridge PMIC-96 for Gram-positive
and NMIC-417 for Gram-negative isolates.
Interpretation and comparison of results
Isolates were classified as susceptible, intermediate or re-
sistant (S/I/R) according to interpreted reports provided
by Alfred 60AST™ and BD Phoenix™. The final report in-
terpretation of susceptibility results provided by Alfred
60 AST™ are based on bacterial growth curve analysis
Fig. 1.
Each sample result by Alfred 60 AST system was com-
pared against BD Phoenix™. Categorical agreement (CA)
Fig. 3 Flowchart of study population. A total of 387 (301 Gram-negative and 86 Gram-positive) valid monomicrobial clinical isolates after 18
excluded samples. Excluded samples comprised 3 polymicrobial and 15 non valid results included 10 system technical failure and 5 no bacterial
detection and subsequently no AST performance
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was defined as agreement of test results interpreted
within the same susceptibility category(S/I/R).
Discordant results were categorized as very major
error (VME, reported susceptible on Alfred AST60™
when reported resistant Phoenix™), major error (ME, re-
ported resistant when susceptible) or minor error (mE,
reported intermediate when susceptible or resistant).
The criteria for antimicrobial susceptibility testing pro-
posed by Jorgensen has been used [26] [27].
Time to AST results
The time to AST was defined as the time between the
culture bottle flagging positive on the BacTec and the
availability of the AST result by Alfred 60 AST system
or BD Phoenix™. Wilcoxon test was performed for com-
parison of median AST time analyses, considering p <
0.05 as a significant value.
SPSS (Statistical Package for the Social Sciences, IBM,
USA) version 25.0 statistics software was used for all
analyses.
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